Mechanistically, the inactivation of TP53 leads to the activation of the Ras/Raf/MEK/ERK pathway and, therefore, the inactivation of GSK3, preventing phosphorylation-dependent degradation of MCL1 in AML [55]. Here, TP53 is linked to acute myeloid leukemia.